Whereas most patients maintained humoral immunity throughout the observation period, we observed reduced cellular immune reactivity as measured by the ancestral-strain-stimulated ELISpot assay in a subset of patients. Half of the individuals (50%; 14/28) maintained cellular immunity three months after the fifth dose, despite acquiring humoral immunity.
19,355 Deaths · 91,095 Hospitalizations · 120,180 Urgent Care · 201,993 Doctor Office Visits · 2,558 Anaphylaxis · 6,418 Bell's Palsy · 2,075 Miscarriages · 9,564 Heart Attacks · 28,908 Myocarditis · 18,982 Permanently Disabled · 9,376 Thrombocytopenia · 15,567 Life Threatening · 37,023 Severe Allergic Reaction · 8,274 Shingles · 5,356 Myocarditis/Pericarditis · 3,744 Thrombocytopenia/Low Platelet ·
·
19,355 Deaths · 91,095 Hospitalizations · 120,180 Urgent Care · 201,993 Doctor Office Visits · 2,558 Anaphylaxis · 6,418 Bell's Palsy · 2,075 Miscarriages · 9,564 Heart Attacks · 28,908 Myocarditis · 18,982 Permanently Disabled · 9,376 Thrombocytopenia · 15,567 Life Threatening · 37,023 Severe Allergic Reaction · 8,274 Shingles · 5,356 Myocarditis/Pericarditis · 3,744 Thrombocytopenia/Low Platelet ·
·